Friday, October 9 – In a new study, GLP-1 users reported nail detachment more than four times as often as nonusers. Waishaw/Getty Images

GLP-1 drugs like Ozempic have been linked to unusual nail changes in a new study.

GLP-1 users reported nail detachment more than four times as often as nonusers, and nail discoloration affected 46% of GLP-1 users, compared with 17% of nonusers.

Thursday, October 8 – A new analysis found that the diabetes medication orforglipron (Foundayo), an oral GLP-1, helped women lose weight regardless of their menopausal status. Healthline/Photo by Eli Lilly

A new analysis of previous studies found that orforglipron promoted weight loss in women regardless of their menopausal status.

This is important since the decline in estrogen after menopause can make weight loss more difficult.

Menopausal women also tend to gain weight around their midsection, which is associated with health risks.

Thursday, October 8 – Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty

People with overweight or obesity who switched from an injectable GLP-1 weight loss medication to the Wegovy (semaglutide) pill lost an average of 4.1% of their body weight over 3 months.

After 3 months, about 2 in 5 participants had lost at least 5% of their body weight.

Thursday, October 8 – Boehringer reports cardiometabolic improvements in people with t2d

Thursday, October 8 – “She definitely wasn’t the same person after starting GLP-1s.”View Entire Post ›

Thursday, October 8 – Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference and other factors—and often leads to rapid weight regain. Results from a pilot randomized trial, published in Obesity Science & Practice, suggest that structured support may attenuate early weight gain after GLP-1 cessation.

Thursday, October 8 – (MedPage Today) — Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure (BP)-lowering benefits, a randomized study found. (BMJ Open Sport & Exercise Medicine…

Thursday, October 8 – (MedPage Today) — What menopause-related information can be tracked by wearable devices such as Apple watches? (New York Times)
GLP-1 medication prescribing surged from 2017 to 2025 among bariatric surgery-eligible teens, yet 9 out of 10 eligible…

Tuesday, September 6 – Recent research suggests that increasing your Ozempic dose may offer greater heart protection than switching to Mounjaro. Eva Kongshavn · Moment/Getty

A real-world study found that people with type 2 diabetes who increased their Ozempic dose rather than switching to Mounjaro had a lower risk of major adverse cardiovascular events (MACE).

Those who increased their Ozempic dose to 2 mg had a 6% lower risk of MACE than those who switched to Mounjaro.

Tuesday, September 6 – Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind, involving more than 2.1 million pregnancies and led by researchers at City St George’s.

Tuesday, October 6 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.

Sunday, October 4 – Welcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd,” I told him.

This week we had a number of prominent deals …

Saturday, October 3 – In the United Kingdom, 2.9% of patients undergoing anesthesia reported receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online Sept. 16 in Anaesthesia to coincide with the annual meeting of the Association of Anaesthetists, held Sept. 16–18 in Liverpool, England.

Saturday, October 3 – (MedPage Today) — The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III trial showed.
Among 1,152 participants, average percentage of body…

Saturday, October 3 – Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.

Friday, October 2 – (MedPage Today) — Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails), compared with patients not taking the drugs, a large prospective…

Friday, October 2 – More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

Friday, October 2 – (MedPage Today) — An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern.
Participants taking 3.6 mg and 6…

Friday, October 2 – (MedPage Today) — Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed.
The percentage of women who initiated a GLP-1 medication within 6 months of delivery rose more than 20-fold, from…

Friday, October 2 – (MedPage Today) — In upstate New York, a nurse was choked with a stethoscope by a patient in the emergency room, according to police. (Syracuse.com)
A family is seeking answers after a patient fell to his death from a sixth floor window of a…

Thursday, October 1 – “Intervening in childhood could save children from decades of irreversible damage,” a transplant surgeon writes of GLP-1 weight loss drugs.

Thursday, October 1 – The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women’s Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women. The authors, that include Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK and colleagues, issue a call to action to improve the evidence based across the board for GLP-1 RA use in women worldwide.

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

Thursday, October 1 – Nail detachment is more than four times as common among people taking GLP-1 receptor agonists as among comparable people with obesity or type 2 diabetes who are not taking the drugs, according to the first controlled study to examine their potential effects on nail health.

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that negatively regulates muscle mass, can reduce lean mass loss during semaglutide treatment by 50% compared with semaglutide and placebo.

Thursday, October 1 – (MedPage Today) — Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven.
Among adults with type 2 diabetes and obesity or overweight at risk for increased cardiovascular…

Thursday, October 1 – Federal prosecutors have charged two people in an alleged scheme to bring fake versions of the type 2 diabetes drug Ozempic from China and sell them to U.S. distributors.

Thursday, October 1 – (MedPage Today) — Use of GLP-1 receptor agonists around pregnancy did not appear to increase adverse maternal or perinatal outcomes, according to two studies.
In a systematic review and meta-analysis of 10 studies representing over 2.1 million…

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight—generally less weight loss than with existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

Thursday, October 1 – Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the University of Georgia suggests patients aren’t taking the weight loss medication as prescribed, often because of high out-of-pocket costs.

Thursday, October 1 – EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and type 2 diabetes, setting up the launch of a Phase 3 trial before the end of the year.

Thursday, October 1 – An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.

Thursday, October 1 – New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Obstetrics, Gynaecology & Women’s Health shows that the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases. The findings are based on a review and meta-analysis of available studies.

Thursday, October 1 – Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.

Thursday, October 1 – New trial data for the weight loss drug called retatrutide shows it helped people living with obesity and type 2 diabetes lose up to 50lbs or 21% of their body weight. Those without diabetes lost up to 70lbs, 25% of body weight, making it the most weight loss ever recorded in a drug trial for diabetes patients. NBC medical contributor Dr. Natalie Azar joins TODAY to break down how the drug compares to GLP-1s.

Wednesday, September 30 – (MedPage Today) — GLP-1s and Stroke

Wednesday, September 30 – (MedPage Today) — The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets) as Class I, its most serious classification. (USA Today)
At least six major U.S. hospitals have shut down…

Tuesday, September 29 – New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.

Tuesday, September 29 – The number of people using GLP-1 treatments like Ozempic and Wegovy for weight loss or chronic conditions has increased rapidly, with more than 1 in 10 U.S. adults currently taking such medications. A new study led by medical students at Virginia Commonwealth University has shed light on how this rise in GLP-1 drug use is affecting Americans’ wallets.